Aveo Forms $15 Million Cancer Deal With J&J Unit

Xconomy Boston — 

Cambridge-based Aveo Pharmaceuticals (NASDAQ: AVEO) has entered into a licensing deal with Centocor Ortho Biotech, a unit of Johnson & Johnson (NYSE: JNJ), according to a press release. The two companies will work together on Aveo’s antibodies targeting the RON (Recepteur d’Origine Nantais) receptor, which may be involved in regulation of tumor growth, cancer survival and metastasis, and bone disruption. The deal is worth $15 million up front to AVEO, plus up to $540 million in milestone payments and royalties.